Jim Cramer on Bristol-Myers Squibb. Co (NYSE:BMY): They Should Have Known Better
We recently published a list of Jim Cramer Discusses These 11 Stocks & Reveals Why Tech Stocks Are Down. In this article, we ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY advanced 1.90% to $60.02 Friday, on what proved to be an all-around dismal trading ...
Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday?
We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Shares of Bristol Myers Squibb Co. slid 3.05% to $59.19 Tuesday, on what proved to be an all-around favorable trading session ...
Zacks.com on MSN3d
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...
Crain's New York Business1d
Bristol-Myers CEO awarded $19M after a difficult year
Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...
Bristol Myers announces CHMP recommendation for Opdivo formulation approval
Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...
Bristol-Myers Squibb Company (BMY): A Bull Case Theory
We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will ...
Bristol Myers announces CHMP opinion recommending Opdivo combination approval
Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...